Caribou Biosciences, Inc
2929 7th Street
Suite 150
Berkeley
California
94710
United States
Tel: 510-982-6030
Website: http://cariboubio.com/
About Caribou Biosciences, Inc
Caribou Biosciences, Inc. is a leading company in CRISPR genome engineering located in Berkeley, CA. Caribou's tools and technologies provide transformative capabilities to therapeutic development, agricultural biotechnology, industrial biotechnology, and basic and applied biological research. The four-year-old company has developed a best-in-class CRISPR genome engineering technology platform and has a leading intellectual property position. The company has established strategic partnerships with DuPont (agriculture, industrial biotechnology) and Genus plc (agriculture) and has co-founded human therapeutics company Intellia Therapeutics (NASDAQ: NTLA.)
32 articles with Caribou Biosciences, Inc
-
Caribou Biosciences announces that JAMS panel issued Interim Award in the arbitration with Intellia Therapeutics
9/26/2019
A three-member JAMS panel issued an Interim Award in the arbitration between Intellia Therapeutics, Inc. and Caribou Biosciences, Inc.
-
Oxford Nanopore Announces That It Has Entered Into a Non-exclusive Agreement With Caribou Biosciences for CRISPR-Cas9 Enrichment for Nanopore Sequencing
9/19/2019
Technology enables targeted sequencing for rapid, precise DNA analysis on portable or large sequencers
-
March is National Women’s Month with March 8 specifically designated as International Women’s Day. Although this is not remotely a comprehensive list, BioSpace recognizes these 10 women (in no particular order) as being especially influential in the biopharma industry.
-
Caribou Biosciences Announces Expansion of Scientific Advisory Board
2/12/2019
The newly appointed members will work with current SAB members and Caribou co-founders Jennifer Doudna, PhD and Martin Jinek, PhD.
-
Caribou Biosciences Appoints Dr. Natalie Sacks to Board of Directors
12/12/2018
Dr. Sacks is an accomplished industry leader and oncology expert who has played a key role in the development and approval of several oncology therapeutics.
-
It was a win for the Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard University, as a federal court of appeals ruled against the University of California (UC) on CRISPR patents.
-
CRISPR pioneer Jennifer Doudna has set up shop in San Francisco’s Gladstone Institutes. Doudna, a UC Berkley professor credited with the co-discovery of CRISPR-Cas9 genome editing technique, will focus on the development of new ways to implement the gene-editing technique for disease treatment.
-
In the biotech world, only 7 to 9 percent of companies have women as their chief executives. Antiva BioSciences is a good example of how this problem is perpetuated.
-
10 Women Biotech CEOs Lead the Charge
6/26/2018
The general consensus is that only about seven to nine percent of chief executive roles in biotech are filled by women. As low as that sounds, it’s better than in the Fortune 500, where only about 4.2 percent are led by female chief executives. -
The U.S. Patent and Trademark Office (USPTO) granted Emmanuelle Charpentier, co-founder of ERS Genomics, the University of California and University of Vienna, their first U.S. patent covering the use of CRISPR/Cas9 for gene editing.
-
There have been a number of leadership changes in biotech companies over the last week. BioSpace has put together a list of new c-suite level hires and position changes.
-
Caribou Biosciences Appoints Timothy F. Herpin, Ph.D. as Chief Business Officer
5/3/2018
Caribou Biosciences, Inc. announced today that it has appointed Timothy F. Herpin, Ph.D. as its first Chief Business Officer.
-
CRISPR, Intellia, Caribou Biosciences And ERS Genomics Announce Appellate Brief Seeking Reversal Of U.S. Patent Board Decision On CRISPR/Cas9 Gene Editing
7/26/2017
-
Caribou Biosciences Appoints Steven B. Kanner, Ph.D. As Chief Scientific Officer
7/6/2017
-
Caribou Biosciences Announces Grant Of A Key CRISPR-Cas9 Genome Editing Patent In Europe
5/10/2017
-
Caribou Biosciences Announces Grant Of A Key CRISPR-Cas9 Patent In The U.S.
5/2/2017
-
Caribou Biosciences And Dupont Pioneer Develop New Method To Comprehensively Map The Off-Target Activity Of CRISPR-Cas9 Across Entire Genomes
5/2/2017
-
Patent Fight Continues as CRISPR, Intellia, Caribou Biosciences and ERS Genomics Appeal CRISPR Decision
4/13/2017
-
CRISPR, Intellia, Caribou Biosciences And ERS Genomics Provide Update On CRISPR/Cas9 U.S. Patent Interference Proceedings And Grants Of Corresponding Patents In The U.K.
2/16/2017
-
The Jackson Laboratory And Caribou Biosciences Announce CRISPR-Cas9 License Agreement
10/25/2016